Factors associated with vaccination against Covid-19 in pregnant and hospitalized postpartum women: A retrospective cohort study

Marcela de Andrade Pereira Silva1*, Helena Fiats Ribeiro1*, Rosana Rosseto de Oliveira2, Fernando Castilho Pelloso1*, Constanza Pujals1*, Raissa Bocchi Pedroso1*, Maria Dalva de Barros Carvalho1*, Sandra Marisa Pelloso1*

1 Department of Post Graduate in Health Science, State University of Maringa, Maringa, Parana, Brazil, 2 Department of Nursing, State University of Maringa, Maringa, Parana, Brazil, 3 Department of Medicine, Federal University of Parana, Curitiba, Parana, Brazil

* These authors contributed equally to this work.

Abstract

Objective
To analyze the characteristics associated with vaccination against Covid-19 in pregnant and postpartum women with Severe Acute Respiratory Syndrome in Brazil and to investigate a possible association between vaccination and the clinical course and outcome of the disease.

Methods
Retrospective cohort study of hospitalized pregnant and postpartum women diagnosed with Severe Acute Respiratory Syndrome (SARS) by SARS-CoV-2, presenting onset of signs and symptoms between May and October 2021. Secondary data were used, available in the Influenza Epidemiological Surveillance Information System (SIVEP-Gripe). Data were analyzed using the SPSS statistical program, medians were applied to present continuous variables and frequencies, and proportions were calculated for categorical variables, using logistic and multivariate regression analysis.

Results
The final study population included 3,585 pregnant and postpartum women, of whom 596 (16.6) were vaccinated: 443 (74.3%) received one dose and 153 (25.7%) received two doses. They were factors associated with non-vaccination against Covid-19 age < 19 anos (OR: 2.57; IC95% 1.40;4.71), non-white women (OR: 1.34; IC95% 1.07;1.67) and those who required ventilatory support (OR: 1.51; IC95% 1.19;1.90) and invasive ventilation (OR: 2.05; IC95% 1.37;3.08). On the other hand, vaccination was associated with advanced maternal age (OR: 0.60; IC95% 0.48;0.76), presence of comorbidities (OR: 0.57; IC95% 0.45;0.72) and loss of taste (OR: 0.63; IC95% 0.48;0.82).
Conclusions
Demographic, ethnic-racial and clinical characteristics were associated with the vaccination status of pregnant and postpartum women with SARS by SARS-CoV-2 in Brazil. Vaccination against Covid-19 in the obstetric population has already shown positive results in the evolution of severe cases, which reiterates its importance. It is essential that health services advance vaccination against Covid-19 in the obstetric population, especially adolescents and non-white women.

Introduction
In December 2019, a new coronavirus (SARS-CoV-2) was identified in the city of Wuhan in China, the causing agent of Covid-19, an acute respiratory disease with a clinical spectrum that ranges from asymptomatic to severe infections. Given its high transmissibility and rapid geographic spread, on March 30, 2020, the World Health Organization (WHO) declared a pandemic status, which resulted in a major challenge for public health authorities worldwide [1]. After 24 months of the pandemic, there were already 485 million cases and 6.1 million deaths worldwide [2].

It is known that the obstetric population is an at-risk group, with a high rate of admission to the intensive care unit (ICU), need for supplemental oxygen and mortality [3, 4]. Brazil has been the country with the highest number of maternal deaths due to Covid-19 worldwide, with a case fatality rate of 7.2% [5]. Faced with this catastrophic pandemic, the scientific community began to develop vaccines against Covid-19 [6, 7].

Moreover, pregnant women were excluded from phase 3 clinical trials of Covid-19 vaccines, resulting in limited data on their efficacy and safety during pregnancy and postpartum. Because of this, in January 2021, the WHO recommended vaccination only for pregnant women who had an unavoidable high risk of exposure, such as health professionals or pregnant women with comorbidities due to the increased risk of serious illness [8].

Nevertheless, in light of new studies [8, 9], and considering that the risks of Covid-19 in the obstetric population outweigh the undocumented and hypothetical risks of Covid-19 vaccines in pregnancy, medical organizations and committees including the American College of Gynecology and Obstetrics (ACOG) [10], Center for Disease Control and Prevention (CDC) [11], the International Federation of Gynecology and Obstetrics (FIGO) [12], and the Brazilian Ministry of Health [13] recommend its use among pregnant and postpartum women.

Given this context and the importance of understanding the impact of vaccination against Covid-19 in the obstetric population, this article aims to analyze the characteristics associated with vaccination against Covid-19 in pregnant and postpartum women with Severe Acute Respiratory Syndrome in Brazil and investigate possible association between vaccination and the clinical course and outcome of the disease.

Methods
A retrospective cohort study of hospitalized pregnant and postpartum women diagnosed with Severe Acute Respiratory Syndrome (SARS) by SARS-CoV-2. The Ministry of Health defines SARS as the individual with flu-like syndrome who has dyspnea/respiratory discomfort, persistent pressure in the chest or O2 saturation lower than 95% in ambient air or cyanosis [14].
Secondary, non-nominal data available in the Influenza Epidemiological Surveillance Information System (SIVEP-Gripe) were used. SIVEP-Gripe was developed in 2009 by the Ministry of Health for SARS surveillance in Brazil, and in 2020 it was redesigned, incorporating the surveillance of SARS cases by SARS-CoV2, currently being the official system for recording SARS cases and deaths in the country. The database was downloaded on November 5, 2021 using the R software.

In Brazil, the National Vaccination Campaign against Covid-19 started on January 18, 2021, however, pregnant and postpartum women were included as a priority group only in the 6th edition of the National Plan for the Operationalization of Vaccination against Covid-19 in Brasil [13], published on April 28, 2021. The study population consisted of pregnant and postpartum women who had the onset of signs and symptoms between May and October 2021 (Epidemiological week 18 to 43).

The cases analyzed comprised the 27 federative units of Brazil, with an estimated population of 213.3 million in 2021. The age group of 10 to 49 years old was delimited for the study population, given in Brazil it is considered a woman in fertile age the one belonging to this group [15]. Cases in which there was no information about the patient’s vaccination status in relation to vaccination against Covid-19, as well as cases in which there was no date for the application of the immunobiological were excluded.

Demographic, ethnic-racial, obstetric characteristics and comorbidities, as well as clinical characteristics and evolution were compared between women who received at least one dose of Covid-19 vaccine before the onset of signs and symptoms, regardless of the type of immunobiological received, and women unvaccinated.

The following independent variables were analyzed: maternal age (< 19 anos; 20 a 34 anos; ≥ 35 anos), obstetric population (pregnant; postpartum women), gestational trimester, race/ethnicity (white; non-white), presence of comorbidities such as: diabetes mellitus, chronic cardiovascular disease, chronic liver disease, chronic neurological disease, chronic kidney disease, chronic hematologic disease, immunodeficiency, asthma and other lung diseases, obesity and obstetric complications including gestational diabetes mellitus, gestational hypertension/pre-eclampsia/eclampsia, and gestational hypothyroidism.

The clinical characteristics analyzed were: symptoms of measured fever, cough, sore throat/odynophagia, dyspnea, respiratory distress, O2 saturation below 95%, diarrhea, vomiting, abdominal pain, fatigue, loss of smell (anosmia), loss of taste (ageusia) and others such as headache, myalgia, asthenia, coryza (nasal discharge), nasal congestion. Need for admission to the intensive care unit (ICU), length of stay in the ICU (< 7 days; > 7 days), need for ventilatory support, need for invasive ventilation, and outcome (cure; death).

Means and standard deviation were used to present continuous variables and frequencies and proportions for categorical variables were calculated. For logistic regression analysis, initially univariate analysis was performed using Pearson’s chi-square, considering p < 0.05 as statistically significant. As a measure of association, the odds ratio (OR) with a confidence interval (CI) of 95% was used. For the multivariate analysis, the independent variables obtained by the univariate analysis with p < 0.20 were considered, and the stepwise forward regression was chosen. The association measure used was the adjusted odds ratio (adjusted OR) with a confidence interval (CI) of 95%, respecting the absence of multicollinearity in the model. Data were analyzed using the SPSS statistical program (Statistical Package for the Social Sciences, version 23, IBM, USA).

All data were obtained from public databases (http://datasus.saude.gov.br/). Because it is public domain data, without the possibility of individual identification, this study does not need approval from na ethics committee, according to Brazilian standards [16].
Results

5,598 SARS cases were reported in pregnant and postpartum women with onset of signs and symptoms between May and October 2021, of which 3,585 (64.0%) were considered eligible. 1,922 cases were excluded for not having information on the vaccination status against Covid-19 and 91 cases for not having a record of the immunobiological application date.

The final study population included 3,585 pregnant and postpartum women, of whom 596 (16.6%) were vaccinated: 443 (74.3%) received one dose and 153 (25.7%) received two doses. The application date of the first dose ranged from $<1$ to 38 weeks before the date of the first signs and symptoms, with a mean of 7 weeks ($\pm 7.4$). Regarding the second dose, the application date ranged from $<1$ to 35 weeks before the date of the first signs and symptoms, with an average of 9 weeks ($\pm 8.3$).

Demographic, ethnic-racial, obstetric characteristics and comorbidities according to vaccination status is shown in Table 1. Compared with unvaccinated women, vaccinated women were older, white and had comorbidities. The proportion of pregnant and postpartum women was equivalent, as well as the gestational trimester. In the univariate analysis, there was an association with vaccination status: age $\leq 19$ years (OR: 2.99; IC$_{95\%}$ 1.76;5.10), age $\geq 35$ years (OR: 0.61; IC$_{95\%}$ 0.51;0.73), race/ethnicity non-white (OR: 1.23; IC$_{95\%}$ 1.02;1.49), presence of comorbidities (OR: 0.64; IC$_{95\%}$ 0.53;0.78) (Table 1).

The clinical evolution of pregnant and postpartum women according to vaccination status is shown in Table 2. Unvaccinated women tended to have symptoms of fever, cough, dyspnea, respiratory distress, O2 saturation below 95%, diarrhea and abdominal pain. Among vaccinated women, the presence of symptoms such as sore throat, vomiting, fatigue, loss of smell, loss of taste and others were more prevalent. The need for ICU hospitalization, ICU stay longer

Table 1. Univariate analysis of demographic, ethnic-racial, obstetric characteristics and comorbidities of pregnant and postpartum women with SARS according to the vaccination status against Covid-19. Brazil, 2021.

| Variables               | n* (%) | Vaccinated | Unvaccinated | Crude OR (IC95%) | p-value |
|-------------------------|--------|------------|--------------|-----------------|---------|
| **Age (years)**         |        |            |              |                 |         |
| $\leq 19$               | 265 (7.4) | 15 | 2.5 | 250 | 8.4 | 2.99 (1.76–5.10) | $<$0.001 |
| 20-34                   | 2299 (64.1) | 350 | 58.7 | 1949 | 65.2 | 1 | |
| $\geq 35$               | 1021 (28.5) | 231 | 38.8 | 790 | 26.4 | 0.61 (0.51–0.73) | $<$0.001 |
| **Race/ethnicity**      |        |            |              |                 |         |
| White                   | 1594 (49.4) | 283 | 53.8 | 1311 | 48.6 | 1 | |
| Non-white               | 1632 (50.6) | 243 | 46.2 | 1389 | 51.4 | 1.23 (1.02–1.49) | 0.028 |
| **Obstetric Population**|        |            |              |                 |         |
| Pregnant                | 2914 (81.3) | 483 | 81.0 | 2431 | 81.3 | 1 | |
| Puerpera                | 671 (18.7) | 113 | 19.0 | 558 | 18.7 | 0.98 (0.78–1.22) | 0.868 |
| **Gestational Age**     |        |            |              |                 |         |
| 1st trimester           | 261 (9.3) | 42 | 9.2 | 219 | 9.3 | 1 | |
| 2nd trimester           | 813 (28.9) | 134 | 29.2 | 679 | 28.8 | 0.97 (0.67–1.42) | 0.882 |
| 3rd trimester           | 1743 (61.9) | 282 | 61.6 | 1459 | 61.9 | 0.98 (0.69–1.40) | 0.934 |
| **Comorbidities**       |        |            |              |                 |         |
| Yes                     | 987 (27.5) | 211 | 35.4 | 776 | 26.0 | 0.64 (0.53–0.78) | $<$0.001 |
| No                      | 2598 (72.5) | 385 | 64.6 | 2213 | 74.0 | 1 | |

*Some information was ignored or blank, which justifies the "n" of some variables being different.

*Considering only the group of pregnant women.

https://doi.org/10.1371/journal.pone.0269091.t001
Table 2. Univariate analysis of clinical characteristics and evolution of pregnant and postpartum women with SARS according to the vaccination status against Covid-19, Brazil, 2021.

| Variables         | \( n^* \) (%) | Vaccinated | Unvaccinated | Crude OR (IC95\%) | p-value |
|-------------------|---------------|------------|--------------|-------------------|---------|
|                   | n | %   | n | %   |                     |         |
| Fever             |   |     |   |     |                     |         |
| Yes               | 1851 (58.2) | 289 55.7 | 1562 58.7 | 1.13 (0.94–1.37) | 0.199   |
| No                | 1328 (41.8) | 230 44.3 | 1098 41.3 | 1                 |         |
| Cough             |   |     |   |     |                     |         |
| Yes               | 2619 (78.7) | 429 78.0 | 2190 78.9 | 1.05 (0.84–1.31) | 0.641   |
| No                | 707 (21.3)  | 121 22.0 | 586 21.1 | 1                 |         |
| Sore Throat       |   |     |   |     |                     |         |
| Yes               | 828 (28.4)  | 143 29.4 | 685 28.2 | 0.94 (0.76–1.17) | 0.593   |
| No                | 2091 (71.6) | 344 70.6 | 1747 71.8 | 1                 |         |
| Dyspnea           |   |     |   |     |                     |         |
| Yes               | 2205 (67.8) | 317 59.1 | 1888 69.5 | 1.57 (1.30–1.90) | <0.001  |
| No                | 1047 (32.2) | 219 40.9 | 828 30.5 | 1                 |         |
| Respiratory Distress |   |     |   |     |                     |         |
| Yes               | 1727 (55.6) | 253 49.4 | 1474 56.8 | 1.35 (1.11–1.63) | 0.002   |
| No                | 1378 (44.4) | 259 50.6 | 1119 43.2 | 1                 |         |
| O2 Saturation <95%|   |     |   |     |                     |         |
| Yes               | 1649 (53.2) | 221 43.5 | 1428 55.1 | 1.59 (1.31–1.93) | <0.001  |
| No                | 1453 (46.8) | 287 56.5 | 1166 44.9 | 1                 |         |
| Diarrhea          |   |     |   |     |                     |         |
| Yes               | 334 (11.8)  | 53 11.2 | 281 20.7 | 1.08 (0.79–1.47) | 0.642   |
| No                | 2500 (88.2) | 422 88.8 | 1078 79.3 | 1                 |         |
| Vomiting          |   |     |   |     |                     |         |
| Yes               | 361 (12.7)  | 68 14.3 | 293 12.4 | 0.85 (0.64–1.12) | 0.248   |
| No                | 2475 (87.3) | 406 85.7 | 2069 87.6 | 1                 |         |
| Abdominal Pain    |   |     |   |     |                     |         |
| Yes               | 294 (10.5)  | 43 9.2  | 251 10.7 | 1.18 (0.84–1.66) | 0.328   |
| No                | 2507 (89.5) | 423 90.8 | 2084 89.3 | 1                 |         |
| Fatigue           |   |     |   |     |                     |         |
| Yes               | 1124 (37.9) | 186 38.3 | 938 37.9 | 0.98 (0.80–1.20) | 0.867   |
| No                | 1839 (62.1) | 300 61.7 | 1539 62.1 | 1                 |         |
| Anosmia           |   |     |   |     |                     |         |
| Yes               | 561 (19.6)  | 108 22.7 | 453 19.0 | 0.80 (0.63–1.02) | 0.068   |
| No                | 2294 (80.4) | 368 77.3 | 1926 81.0 | 1                 |         |
| Ageusia           |   |     |   |     |                     |         |
| Yes               | 510 (17.9)  | 106 22.3 | 404 17.0 | 0.72 (0.56–0.91) | 0.007   |
| No                | 2336 (82.1) | 370 77.7 | 1966 83.0 | 1                 |         |
| Other symptoms    |   |     |   |     |                     |         |
| Yes               | 1411 (48.8) | 262 54.9 | 1149 47.6 | 0.75 (0.61–0.91) | 0.004   |
| No                | 1478 (51.2) | 215 45.1 | 1263 52.4 | 1                 |         |
| ICU admission     |   |     |   |     |                     |         |
| Yes               | 1105 (32.5) | 158 28.0 | 947 33.4 | 1.29 (1.06–1.58) | 0.011   |
| No                | 2292 (67.5) | 407 72.0 | 1885 66.6 | 1                 |         |
| ICU stay          |   |     |   |     |                     |         |
| \( \leq \) 7 days | 300 (44.0)  | 47 63.5 | 253 41.6 | 1                 |         |
| > 7 days          | 382 (56.0)  | 27 36.5 | 355 58.4 | 2.44 (1.48–4.03) | <0.001  |
| Ventilatory support |   |     |   |     |                     |         |
| Yes               | 1992 (60.1) | 282 51.0 | 1710 62.0 | 1.57 (1.30–1.88) | <0.001  |

(Continued)
than 7 days, need for ventilatory support, need for invasive ventilation and evolution to death prevailed among unvaccinated women (Table 2).

The univariate analysis showed an association with vaccination status: dyspnea (OR: 1.57; IC95% 1.30–1.90), respiratory distress (OR: 1.35; IC95% 1.11–1.63), O2 saturation lower than 95% (OR: 1.59; IC95% 1.31–1.93), loss of taste (OR: 0.72; IC95% 0.56–0.91), other symptoms (OR: 0.75; IC95% 0.61–0.91), ICU admission (OR: 1.29; IC95% 1.06–1.58), ICU stay longer than 7 days (OR: 2.44; IC95% 1.48–4.03), need for ventilatory support (OR: 1.57; IC95% 1.30–1.88), need for invasive ventilation (OR: 2.14; IC95% 1.57–2.93) and death (OR: 1.71; IC95% 1.22–2.40) (Table 2).

Women who required ventilatory support and invasive ventilation were 1.51 and 2.05 times more likely to be unvaccinated, respectively. The extremes of maternal age were associated with vaccination in different ways, where adolescents were 2.05 times more likely to be unvaccinated, while advanced maternal age proved to be a protective factor against non-vaccination. Loss of taste was the only symptom that remained independently associated with vaccination. As for race/ethnicity, it was identified that non-white women were 1.34 times more likely to be unvaccinated. Table 3 presents the multivariate logistic regression analysis.

**Discussion**

The findings of this study show that maternal age ≤19 years, non-white women and who required ventilatory support and invasive ventilation were factors associated with non-vaccination against Covid-19 in pregnant and postpartum women with SARS by SARS-CoV-2 in

### Table 2. (Continued)

| Variables          | n* (%) | Vaccinated | Unvaccinated | Crude OR (IC95%) | p-value |
|--------------------|--------|------------|--------------|-----------------|---------|
|                    | n      | %          | n            |                 |         |
| No                 | 1320 (39.9) | 271 (49.0) | 1049 (38.0) | 1               |         |
| Invasive Ventilation| Yes    | 515 (15.5) | 48 (8.7)     | 467 (16.9)      | 2.14 (1.57–2.93) | <0.001  |
|                    | No     | 2797 (84.5)| 505 (91.3)   | 2292 (83.1)     | 1       |         |
| Outcome            | Cure   | 2705 (87.3)| 450 (91.6)   | 2255 (86.5)     | 1       |         |
|                    | Death  | 393 (12.7) | 41 (8.4)     | 352 (13.5)      | 1.71 (1.22–2.40) | 0.002   |

Some information was ignored or blank, which justifies the “n” of some variables being different.

https://doi.org/10.1371/journal.pone.0269091.t002

---

### Table 3. Multiple logistic regression analysis of factors associated with the vaccination status against Covid-19 in pregnant and postpartum women with SARS.

| Variables                          | n (%) | Adjusted OR (IC95%) | p-value |
|------------------------------------|-------|---------------------|---------|
| Demographic characteristics and comorbidities |       |                     |         |
| Age ≤ 19 years                     | 265 (7.4) | 2.57 (1.40–4.71)   | 0.002   |
| Age ≥ 35 years                     | 1021 (28.5)| 0.60 (0.48–0.76)   | <0.001  |
| Non-white                          | 1632 (50.6)| 1.34 (1.07–1.67)   | 0.009   |
| Comorbidities                      | 987 (27.5)| 0.57 (0.45–0.72)   | <0.001  |
| Clinical characteristics           |       |                     |         |
| Ventilatory support                | 1992 (60.1)| 1.51 (1.19–1.90)   | 0.001   |
| Invasive ventilation               | 515 (15.5)| 2.05 (1.37–3.08)   | <0.001  |
| Loss of taste                      | 510 (17.9)| 0.63 (0.48–0.82)   | 0.001   |

https://doi.org/10.1371/journal.pone.0269091.t003
Brazil. The factors associated with vaccination against Covid-19 were advanced maternal age, presence of comorbidities and the loss of taste symptom.

The Brazilian Ministry of Health, in its first edition of the National Vaccination Plan against Covid-19 published in December 2020 [17], contraindicated vaccination in pregnant women due to the lack of data on its efficacy and safety during pregnancy, however in its second edition, published in January 2021 [18], vaccination was recommended for pregnant women, as long as they belong to one of the priority groups and the decision-making is conditioned to a joint deliberation between the woman and the health team responsible for her care. Only in the sixth edition, published in April 2021, the population of pregnant and postpartum women were included as a priority group for vaccination [13].

However, vaccination against covid-19 in pregnant and postpartum women, without risk factors, was temporarily interrupted from 05/19 to 07/06/2021 in Brazil, after the notification of a post-vaccination thromboembolic adverse event in a pregnant woman. During this period, vaccination was maintained only for pregnant and postpartum women with comorbidities [19]. Thus, it is possible to understand the association identified in the present study between the presence of comorbidities and vaccination against Covid-19.

Studies have shown that pregnant and postpartum women with comorbidities are at high risk of developing more severe cases of Covid-19, in addition to unfavorable maternal-fetal outcomes [4, 20], which justifies the prioritization of vaccination for these women. However, in the current context, it is necessary to establish actions by public authorities and managers that guarantee the vaccination of the entire obstetric population, regardless of added risk factors, in addition to actions that increase this population’s adherence to vaccination, such as reducing barriers that make it difficult to access health services, spread adequate and evidence-based information by health professionals, and combat the circulation of false news.

With regard to maternal age, vaccination in adolescents aged 12 to 17 years old started only in September 2021 in Brazil, after publication of the technique note n°45/2021 [21]. In view of this, the association identified in the present study in relation to maternal age ≤ 19 years and non-vaccination against Covid-19 is understandable, given that vaccination was not available for this public during a large extent of the study period. Regarding advanced maternal age (≥ 35 years) have been associated with vaccination, it is believed that is related to the presence of comorbidities, since the frequency of pre-existing chronic diseases increases with age, presenting higher proportions in women with advanced maternal age [22].

Studies published in the context of the Covid-19 pandemic show increased racial inequality, since the black population, in particular, is at greater risk of disparities in access to health services [23], which has resulted in a higher proportion of cases and deaths from Covid-19 in this population, a problem already evidenced in Brazil and the United States [24–27]. With regard to the obstetric population, a study carried out in 2020 with 12,556 pregnant and postpartum women with SARS due to Covid-19 in Brazil, showed that deaths from Covid-19 were twice as high in women who called themselves black, when compared to white women [28]. It is known that in Brazil, racial disparities in maternal mortality existed even before the pandemic, when the number of deaths among black, brown and indigenous women was disproportionately higher [29].

In view of this history and current evidence on racial disparities in health care in Brazil, and in view of the result of the present study, which identifies a greater chance of non-white women not being vaccinated, it is observed that racial disparities have also had an effect on vaccination against Covid-19. A study carried out in Maryland, USA, identified lower vaccination rates against Covid-19 when compared to regions with predominantly white populations [30].
It is known that the phenotypic characteristics of SARS-CoV-2 infection range from the complete absence of symptoms, mild and moderate clinical manifestations, to severe forms with possible pulmonary insufficiency and eventually death [31]. Incidentally, studies carried out in Brazil have identified a prevalence of pregnant and postpartum women with SARS who required ICU admission of approximately 20%, use of ventilatory support in 22%, and need for invasive ventilation ranging from 10% to 25% of cases [32, 33].

One of the objectives of vaccination is to prevent those infected from evolving into severe and critical cases of the disease [34]. Therefore, it is understood that the present findings on women who required ventilatory support and mechanical ventilation were more likely to be unvaccinated, demonstrating the possible positive impact of vaccination in the prevention of critical cases of the disease.

The only symptom that remained independently associated with the vaccination status of the study population was loss of taste, technically defined as ageusia, which in the present study was protective against non-vaccination. A study carried out with 417 patients with mild to moderate COVID-19 identified that 88% of the patients lost their sense of smell and taste during the virus infection [35]. It is hypothesized that the positive impact of vaccination on the severe course of the disease causes frequent symptoms to prevail among the vaccinated group in milder cases, such as ageusia.

This study has limitations, since it analyzes secondary data, where the lack of registration or the low quality of the data are common and cannot exclude the possibility of errors in the registration of the data. However, it is understood that the health information systems of the Brazilian Ministry of Health are of great value, as they have information that help in the planning of health policies and programs, contributing to the decision-making process. In addition, during the Covid-19 pandemic, SIVEP-Gripe has been the main source of data in the country.

Another limitation is that in this study, the group of vaccinated women consisted of all women who received at least one dose of the vaccine, regardless of the time interval between vaccination and the onset of signs and symptoms, which requires caution in interpretation of the results, since it is not an effectively immunized population.

In view of the findings, it is essential that health services advance in the vaccination of the obstetric population, especially adolescents, due to the low proportion identified. In addition, policies that address racial disparities are essential in order to contribute to improving the vaccination among black, brown and indigenous women. Vaccination against Covid-19 in the obstetric population already shows a positive impact on the evolution of severe cases, specifically, in cases of respiratory failure requiring ventilatory support and invasive ventilation, which reiterates the importance of vaccination against Covid-19.

**Author Contributions**

**Conceptualization:** Marcela de Andrade Pereira Silva, Helena Fiats Ribeiro, Sandra Marisa Pelloso.

**Data curation:** Marcela de Andrade Pereira Silva, Helena Fiats Ribeiro, Rosana Rosseto de Oliveira.

**Formal analysis:** Helena Fiats Ribeiro, Fernando Castilho Pelloso, Sandra Marisa Pelloso.

**Investigation:** Marcela de Andrade Pereira Silva, Helena Fiats Ribeiro.

**Methodology:** Marcela de Andrade Pereira Silva, Helena Fiats Ribeiro, Constanza Pujals, Raissa Bocchi Pedroso, Maria Dalva de Barros Carvalho.

**Project administration:** Marcela de Andrade Pereira Silva.
**Supervision:** Sandra Marisa Pelloso.

**Writing – original draft:** Marcela de Andrade Pereira Silva, Helena Fiats Ribeiro.

**Writing – review & editing:** Rosana Rosseto de Oliveira, Fernanda Castilho Pelloso, Constanza Pujals, Raissa Bocchi Pedroso, Maria Dalva de Barros Carvalho, Sandra Marisa Pelloso.

**References**

1. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19–11 March 2020. Geneva (CH): WHO; 2020. [cited 16 Apr 2021]. https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-and-final-11mar2020.pdf

2. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Geneva (CH) WHO; 2021. [cited 20 Apr 2021] https://covid19.who.int

3. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status—United States, January 22–October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69 (44):1641–47. https://doi.org/10.15585/mmwr.mm6944es PMID: 33151521

4. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020; 370:m3320. https://doi.org/10.1136/bmj.m3320 PMID: 32873575

5. Ministério da Saúde (BR). Fundação Osvaldo Cruz. Boletim observatório Covid-19. Semanas epidemiológicas 20 e 21. Brasília, DF; 2021 [cited 20 May 2021] https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/u34/boletim_covid_2021-semanas_20-21-red.pdf

6. Koirala A, Joo YJ, Khatami A, Chiu C, Britton PN. Vaccines for COVID-19: the current state of play. Paediatr Respir Rev. 2020; 35: 43–9. https://doi.org/10.1016/j.prrv.2020.06.010 PMID: 32653463

7. World Health Organization. WHO Coronavirus Disease (COVID-19) Vaccines. Geneva (CH): WHO; 2021 [cited 06 Jun 2021] https://extranet.who.int/pqweb/vaccines/covid-19-vaccines

8. Brillo E, Tosto V, Gerli S, Buonomo E. COVID-19 vaccination in pregnancy and postpartum. J Mater Fetal Neonatal Med. 2021:1–20. https://doi.org/10.1080/14767058.2021.1920916 PMID: 33998379

9. Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. N Engl J Med. 2021; 384(24):2273–82. https://doi.org/10.1056/NEJMoa2104983 PMID: 33882218

10. The American College of Obstetricians and Gynecologists (ACOG). COVID-19 Vaccines and Pregnancy: Key recommendations and Messaging for Clinicians. 2021 [cited 02 Oct 2021] https://www.acog.org/covid-19/covid-19-vaccines-and-pregnancy-conversation-guide-for-clinicians

11. Centers for Disease Control and Prevention (US). Vaccination Considerations for People who are Pregnant or Breastfeeding. 2021 [cited 02 Oct 2021] https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html

12. International Federation of Gynecology and Obstetrics (FIGO). COVID-19 Vaccination for Pregnant and Breastfeeding Women. 2021 [cited 03 Oct 2021] https://www.figo.org/covid-19-vaccination-pregnant-and-breastfeeding-women

13. Ministério da Saúde (BR). Plano Nacional de Operacionalização da vacinação contra a covid-19. 6ª edição. Brasília: Ministério da Saúde; 2021 [cited 10 Oct 2021] https://www.conasems.org.br/wp-content/uploads/2021/04/6a-Edic%CC%81a%CC%83o-Plano-Vacina%CC%81a%CC%83o-contra-Covid_V5_27abr21.pdf

14. Ministério da Saúde (BR). Guia de vigilância epidemiológica. Emergência de saúde pública de importância nacional pela doença pelo coronavírus 2019. Brasília: Ministério da Saúde; 2020 [cited 20 Oct 2021] https://portalarquivos.saude.gov.br/images/pdf_gvs_coronavirus_6ago20_ajustes-finais-2.pdf

15. Ministério da Saúde (BR). Portaria n° 1.119, de 5 de Junho de 2008. Regulamenta a vigilância de óbitos maternos. Diário Oficial da União de 2008. [cited 21 Mar 2021] https://bvsms.saude.gov.br/bvs/saudelegis/gm/2008/prt1119_05_06_2008.html

16. Conselho Nacional de Saúde (BR). Resolução n° 510, de 7 de Abril de 2016. Dispõe sobre as normas aplicáveis a pesquisas em Ciências Humanas e Sociais [cited 01 Apr 2021] http://conselho.saude.gov.br/resolucoes/2016/Reso510.pdf
17. Ministério da Saúde (BR). Plano Nacional de Operacionalização da vacinação contra a covid-19. 1ª edição. Brasília: Ministério da Saúde, 2020 [cited 01 Apr 2021] https://www.conasems.org.br/wp-content/uploads/2021/04/1a-Edic%C3%A7%C3%A3o-Plano-Nacional-de-Vacina%C3%A7%C3%A3o-contra-Covid-19.pdf

18. Ministério da Saúde (BR). Plano Nacional de Operacionalização da vacinação contra a covid-19. 2ª edição. Brasília: Ministério da Saúde, 2021 [cited 01 Apr 2021] https://www.conasems.org.br/wp-content/uploads/2021/04/2a-Edi%C3%A7%C3%A3o-Plano-Nacional-de-Vacina%C3%A7%C3%A3o-contra-Covid_v2_25jan21.pdf

19. Ministério da Saúde (BR). Secretaria de Vigilância em Saúde. Departamento de Imunizações. Coordenadoria-Geral do Programa Nacional de Imunizações. Nota técnica n°: 651/2021-CGPNI/DEI/TV/SVS/MS. [cited 01 Apr 2021]

20. Menezes MO, Takemoto MLS, Nakamura-Pereira M, Katz L, Amorim MMR, Salgado HO, et al. Risk factors for adverse outcomes among pregnant and postpartum women with acute respiratory distress syndrome due to COVID-19 in Brazil. International Journal of Gynecology & Obstetrics. 2020; 151(3):415–23. https://doi.org/10.1002/ijgo.19407 PMID: 33011966

21. Ministério da Saúde (BR). Secretaria Extraordinária de Enfrentamento à COVID-19. Nota Técnica n° 45/2021-SECOVID/GAB/SECOVID/MS. Brasília: Ministério da Saúde, 2021 [cited 28 Sep 2021] https://sbim.org.br/images/files/notas-tecnicas/sei-ms-secovida-libera-vacinacao-adolescentes-210922.pdf

22. Nieto MC, Barrabés EM, Martínez SG, Prat MG, Serra BS. Impact of aging on obstetric outcomes: defining advanced maternal age in Barcelona. BMC Pregnancy and Childbirth. 2019; 19(342):1–10. https://doi.org/10.1186/s12884-019-2415-3 PMID: 31547808

23. Goes EF, Ramos DO, Ferreira AJF. Desigualdades raciais em saúde e a pandemia da Covid-19. Trabalho Educ Saúde. 2020; 18(3):1–7. https://doi.org/10.1590/1806-9282.67.01.34185314

24. Gurrenda S, Castro MC. COVID-19 poses alarming pregnancy and postpartum mortality risk in Brazil. E Clinical Medicine. 2021; 36:100917. https://doi.org/10.1016/j.eclinm.2021.100917 PMID: 34124636

25. Moore JT, Ricaldi JN, Rose CE, Fuld J, Parise M, Kang GJ, et al. Disparities in Incidence of COVID-19 Among Underrepresented Racial/Ethnic Groups in Counties Identified as Hotspots During June 5–18, 2020–22 States, February–June 2020. MMWR Morbidity and Mortality Weekly Report. 2020; 69(33):1122–6. https://doi.org/10.15585/mmwr.mm6933e1 PMID: 32817602

26. Santos DS, Menezes MO, Andreucci CB, Nakamura-Pereira M, Knobel R, Katz L, et al. Disproportionate impact of Coronavirus Disease 2019 (COVID-19) among pregnant and postpartum Black Women in Brazil through structural racism lens. Clin Infect Dis. 2020; 72(11):2068–9. https://doi.org/10.1093/cid/ciaa1066 PMID: 32719866

27. Dalsania AK, Fastiggi MJ, Kahlam A, Shah R, Patel K, Shiau S, et al. The Relationship Between Social Determinants of Health and Racial Disparities in COVID-19 Mortality. J Racial Ethn Health Disparities. 2021; 8(6):2021–8. https://doi.org/10.1007/s40615-020-00952-y PMID: 33403652

28. Scheler CA, Discacciati MG, Vale DB, Lajos GJ, Surita F, Teixeira JC. Mortality in pregnancy and the postpartum period in women with severe acute respiratory distress syndrome related to COVID-19 in Brazil, 2020. Int J Gynaecol Obstet. 2021; 155(3):475–82. https://doi.org/10.1002/ijgo.13804 PMID: 34185314

29. Alves LGR, Guimarães RM. Race inequalities in maternal mortality in the city of Rio de Janeiro, Brazil: 2010–2019. Rev Assoc Med Bras. 2021; 67(1):120–4. https://doi.org/10.1590/1806-9282.67.01.20200633 PMID: 34161474

30. Cardona S, Felipe N, Fischer K, Sehgal NJ, Schwartz BE. Vaccination Disparity: Quantifying Racial Inequity in COVID-19 Vaccine Administration in Maryland. Journal of Urban Health. 2021; 98(4):464–8. https://doi.org/10.1002/j.1097-4571.2021.101620 PMID: 34563490

31. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5 PMID: 31986264

32. Godoi APN, Bernardes GCS, Almeida NA, Melo SN, Belo VS, Nogueira LS, et al. Síndrome Respiratória Aguda Grave em gestantes e puérperas portadoras da COVID-19. Rev Bras Saude Mater Infant. 2021; 30(Supl 2):471–80.

33. Leal LF, Merckx J, Fell DB, Kuchenbecker R, Miranda AE, de Oliveira WK, et al. Characteristics and outcomes of pregnant women with SARS-CoV-2 infection and other severe acute respiratory infections (SARI) in Brazil from January to November 2020. Braz J Infect Dis. 2021; 25(5):101620. https://doi.org/10.1016/j.bjid.2021.101620 PMID: 34563490

34. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised
controlled trials in Brazil, South Africa, and the UK. The Lancet. 2020; 397(10269):99–111. https://doi.org/10.1016/S0140-6736(20)32661-1 PMID: 33306989

35. Lechien JR, Chiesa-Estoomba CM, Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch of Otorhinolaryngol. 2020; 277(8):2251–61. https://doi.org/10.1007/s00405-020-05965-1 PMID: 32253535